Current and Previous PGY2 Infectious Diseases Residents University of Colorado School of Pharmacy/UCHealth University of Colorado Hospital

- <u>Dorie Hoody, Pharm.D., BCPS</u> (Infectious Diseases Specialty Residency, 2001-2002): Senior Clinical Instructor, Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences. Formerly Clinical Specialist in Infectious Diseases & Drug Information Services, University of Colorado Hospital, Denver, CO.
 - Kiser TH, Hoody DW, Obritsch MD, Wegzyn CO, Bauling PC, Fish DN. Evaluation of levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury. Antimicrobial Agents and Chemotherapy 2006; 50:1937-1945.
- 2. <u>Colleen Wegzyn, Pharm.D.</u> (Infectious Diseases Specialty Residency, 2002-2003): Clinical Science Manager, Abbott Nutrition, Denver, CO. Formerly Clinical Sciences Liaison for Infectious Diseases/HIV, Roche Pharmaceuticals, Denver, CO.
- 3. <u>Deborah Anderson, Pharm.D., BCCCP</u> (Infectious Diseases Specialty Residency, 2003-2004): Clinical Pharmacist in Infectious Diseases and Critical Care, Denver Health Medical Center, Denver, CO.
 - Anderson D, Fish DN, Hilts A. An assessment of antipseudomonal antimicrobial usage: the impact of antimicrobial restrictions. 44th Annual Meeting of the American Society for Microbiology, Washington, DC. October, 2004. Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy 2004:753 (abstract C2-1985).
- Joshua Schwiesow, Pharm.D., BCPS (Infectious Diseases Specialty Residency, 2004-2005): Clinical Specialist in Infectious Diseases, Kaiser Permanente of Colorado, Denver, CO. Formerly Clinical Pharmacist in Infectious Diseases, National Jewish Medical and Research Center, Denver, CO.
- 5. <u>Joel Coon, Pharm.D., BCACP</u> (Infectious Diseases Specialty Residency, 2005-2006): Staff Pharmacist, South Peninsula Hospital, Homer, AK.
- 6. <u>Stephanie Kuhn, Pharm.D., BCPS AQ-ID (</u>Infectious Diseases Resident, 2012-2013): Antimicrobial Stewardship Pharmacist, Wesley Medical Center, Wichita, KS.
 - Kuhn S, Winterland J, Goolsby T, Barron M, Barber G, Fish DN. Daptomycin: Increasing appropriateness and decreasing costs through antimicrobial stewardship interventions. 53rd Annual Meeting of the American Society for Microbiology, Denver, CO. September 10-13, 2013. **Abstracts of the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy** 2013: abstract K-1288.
 - Kuhn S, Goolsby T, Barron M, Barber G, Fish D. A Retrospective Analysis on the Impact of Pharmacist Interventions on Antimicrobial Stewardship. 16th Annual Making a Difference in Infectious Diseases Pharmacotherapy (MAD-ID) Meeting, Orlando, FL. May 9-12, 2013.

- Matthew Miller, Pharm.D., BCPS AQ-ID (Infectious Diseases Resident, 2013-2014): Clinical Specialist in Infectious Diseases/Antimicrobial Stewardship, Children's Hospital Colorado, Aurora, CO. Formerly Clinical Specialist in Infectious Diseases/Antimicrobial Stewardship, UCHealth/University of Colorado Hospital, Aurora, CO; and Clinical Specialist in Infectious Diseases/Emergency Medicine, Trinity Mother Frances Health System, Tyler, TX.
 - Miller MA, Fish DN, Goolsby TA, Barber GA, Mueller SW. Comparison of treatment outcomes and safety with nafcillin or cefazolin for the management of methicillinsensitive Staphylococcus aureus bacteremia. 54th Annual Meeting of the American Society for Microbiology, Washington, DC. September 6-9, 2014. Abstracts of the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy 2014: abstract L-405.
 - Miller MA, Fish DN, Barber GR, Barron MA, Goolsby TA, Mueller SW. Cefazolin versus Nafcillin for Methicillin-Susceptible Staphylococcus aureus Bloodstream Infections. **Journal of Microbiology, Immunology, and Infection** 2018; Aug 18. pii: S1684-1182(18)30304-9. doi: 10.1016/j.jmii.2018.07.006.
- 8. <u>Amber Streifel</u>, Pharm.D., BCPS (Infectious Diseases Resident, 2014-2015): Infectious Diseases/Antimicrobial Stewardship Pharmacist, Oregon Health & Science University, Portland, OR. Formerly Infectious Diseases/Antimicrobial Stewardship Pharmacist, St. Mary's Medical Center, Grand Junction, CO.
 - Streifel A, Schoeppler K, Zamora M, Fish DN. Treatment of Respiratory Syncytial Virus (RSV), Parainfluenza Virus (PIV), and Human Metapneumovirus (hMPV) with Ribavirin in Lung Transplant Recipients. ID Week 2015, San Diego, CA. October 7-11, 2015. ID Week 2015 Abstracts 2015: abstract 1196.
- 9. <u>Alexander Novin</u>, Pharm.D., BCPS, BCIDP (Infectious Diseases Resident, 2015-2016): Infectious Diseases/Antimicrobial Stewardship Pharmacist, UCHealth/Memorial Medical Center, Colorado Springs, CO.
 - Novin AR, Miller MA, Perterson EL, Schoeppler KE, Barber GR, Mueller SW, McCollister BD, Fish D. Predictors of mortality associated with enterococcal bacteremia. 19th Annual Making a Difference in Infectious Diseases Pharmacotherapy (MAD-ID) Meeting, Orlando, FL. May 5-7, 2016.
- 10. <u>Kelsey Melander, Pharm.D., BCIDP</u> (Infectious Diseases Resident, 2016-2017): Antimicrobial Stewardship Clinical Pharmacist, Rose Medical Center, Denver, CO.
 - Melander K, Miller M, Fish D, Barber G, Bickel A, Weinberg A. Evaluation of the viral respiratory PCR panel on healthcare utilization. 20th Annual Making a Difference in Infectious Diseases Pharmacotherapy (MAD-ID) Meeting, Orlando, FL. May 10-13, 2017.

- Nichole Neville, Pharm.D., BCIDP (Infectious Diseases Resident, 2017-2018):
 Antimicrobial Stewardship Clinical Pharmacist, Swedish Medical Center, Englewood, CO.
 - Neville NR, Yang ES, Wong FH, Miller MA, Barber GR, Kaiser JN, Tobin JK, Gutman JA. Evaluation of an Oral Ribavirin Protocol for Treating Community Acquired Respiratory Virus (CARV) Infections in Patients with Hematologic Malignancy. 21st Annual Making a Difference in Infectious Diseases Pharmacotherapy (MAD-ID) Meeting, Orlando, FL. May 9-12, 2018.
 - Morrisette T, Neville N, Britton A, Mueller SW, Jacknin G, Miller MA, Fish DN.
 Pharmacokinetic and pharmacodynamics evaluation of cefepime in overweight and
 obese patients. ID Week 2019, Washington DC. October 3-6, 2019. ID Week 2019
 Abstracts 2019: abstract 1535.
- 12. <u>Taylor Morrisette, Pharm.D</u> (Infectious Diseases Resident, 2018-2019): Assistant Professor of Pharmacy, Wingate University School of Pharmacy, Wingate, NC. Formerly Postdoctoral Research Fellow in Health Outcomes and Pharmacokinetics/Pharmacodynamics, Wayne State University, Detroit, MI.
 - Morrisette T, Van Matre A, Miller MA, Mueller SW, Bajrovic V, Abidi MZ, Benamu E, Kaiser JN, Barber G, Chase S, Tobin J, Fish DN, Gutman JA, Oral Vancomycin Prophylaxis as Secondary Prevention for *Clostridioides difficile* Infection in the Hematopoietic Stem Cell Transplant and Hematologic Malignancy Population.
 Biology of Blood and Marrow Transplantation 2019; doi.org/10.1016/j.bbmt.2019.06.021.
 - Morrisette T, Neville N, Britton A, Mueller SW, Jacknin G, Miller MA, Fish DN.
 Pharmacokinetic and pharmacodynamics evaluation of cefepime in overweight and obese patients. ID Week 2019, Washington DC. October 3-6, 2019. ID Week 2019
 Abstracts 2019: abstract 1535.
 - Morrisette T, Da Silva B, Mueller SW, Damioli L, Krsak M, Miller MA, Fish DN. Real-world use of tedizolid phosphate: a case series of long-term tolerability. ID Week 2019, Washington DC. October 3-6, 2019. ID Week 2019 Abstracts 2019: abstract 2285.
 - Morrisette T, Molina KC, Da Silva B, Mueller SW, Damioli L, Krsak M, Miller MA, Fish DN. Real World Use of Tedizolid Phosphate for 28 Days or More: A Case Series Describing Tolerability and Clinical Success. Open Forum Infectious Diseases 2022; May 23;9(6):ofac028. doi: 10.1093/ofid/ofac028. eCollection 2022 Jun. PMID: 35615295.
- Kyle Molina, Pharm.D. (Infectious Diseases Resident, 2019-2020): Clinical Specialist in Infectious Diseases/Antimicrobial Stewardship, Scripps Memorial Hospital, La Jolla, CA. Formerly Clinical Specialist in Infectious Diseases/Antimicrobial Stewardship, UCHealth/University of Colorado Hospital, Aurora, CO.
 - Molina KC, Morrisette T, Miller MA, Huang V, Fish DN. The Emerging Role of β-lactams in the Treatment of Methcillin-Resistant *Staphylococcus aureus* Blood Stream Infections. **Antimicrobial Agents and Chemotherapy**. 2020 Jun; 64(7)e00468-20. Editor's Pick Distinction.
 - Krsak M, Morrisette T, Miller MA, Molina KC, Huang M, Damioli L, Pisney L, Wong M, Poeschla E. Advantages of Outpatient Treatment for Serious Gram-positive Infections with Long-acting Lipoglycopeptides: A Review. Pharmacotherapy. 2020 May;40(5):469-478.

- Boyle E, Dorgan E, Lunowa C, Molina KC, Johnson T, Miller MA, Huang M, Fish DN. External Validation of the Methicillin-Resistant Staphylococcus aureus Bacteremia Score. IDWeek 2020 abstracts.
- Ngo N, Sielatchom-Noubissie L, Molina KC, Johnson T, Huang M, Hojat L, Kiser T, Miller MA. Comparison of Oral Beta-Lactams and Fluoroquinolones for Step-Down in Uncomplicated Enterobacterales Blood Stream Infections. IDWeek 2020 abstracts.
- Morrisette T, Molina KC, Da Silva B, Mueller SW, Damioli L, Krsak M, Miller MA, <u>Fish DN</u>. Real World Use of Tedizolid Phosphate for 28 Days or More: A Case Series Describing Tolerability and Clinical Success. **Open Forum Infectious Diseases** 2022; May 23;9(6):ofac028. doi: 10.1093/ofid/ofac028. eCollection 2022 Jun. PMID: 35615295.
- 14. <u>Tanner Johnson, Pharm.D.</u> (Infectious Diseases Resident, 2020-2021): Antimicrobial Stewardship Pharmacist, Mayo Clinic, Rochester, MN.
 - Johnson TM, Howard AH, Miller MA, Allen LL, Huang M, Molina KC, Bajrovic V. Effectiveness of bezlotoxumab for prevention of recurrent *Clostridioides difficile* infection among transplant recipients. Open Forum Infectious Diseases; 2021 Jun 4:8(7):ofab294.
 - Johnson TM, Molina KC, Miller MA, Kiser TH, Huang M, Mueller SW. Combination ceftaroline and daptomycin salvage therapy for complicated methicillin-resistant *Staphylococcus aureus* bacteraemia compared with standard of care. International Journal of Antimicrobial Agents 2021; Apr;57(4):106310.
 - Boyle E, Dorgan E, Lunowa C, Molina K, Johnson T, Miller M, Huang M, Fish D. External Validation of the Methicillin-Resistant Staphylococcus aureus Bacteremia Score. IDWeek 2020 abstracts.
- 15. <u>Williams Monier Texidor, Pharm.D.</u> (Infectious Diseases Resident, 2021-2022): Oncology Pharmacist, Miami Cancer Institute/Baptist Health South Florida, Miami, FL

Projects:

- Monier Texidor W, Miller MA, Molina KC, Krsak M, Calvert B, Hart C, Storer M, Fish DN. Oritavancin as Sequential Therapy for Gram-positive Bloodstream Infections. BMC Infectious Diseases, In press 2023.
- Evaluation of daptomycin or linezolid monotherapy vs. combination therapy of daptomycin + a beta-lactam for VRE infections.
- Development and implementation of a protocol for empiric dose adjustment of antimicrobials in patients with augmented renal clearance
- 16. <u>Madison Salam, Pharm.D.</u> (Infectious Diseases Resident, 2022-2023): Clinical Specialist in Infectious Diseases/Antimicrobial Stewardship, UCHealth University of Colorado Hospital, Aurora, CO.

Projects:

- Effectiveness of oral amoxicillin/clavulanate for cystitis caused by ESBL-producing Enterobacterales
- Effectiveness of bezlotoxumab alone or in combination with various antibiotics for Clostridioides difficile infection

17. Blake Jennewein, Pharm.D.: Infectious Diseases Resident, 2023-2024:

Projects:

- Institutional effectiveness and stewardship implications of changing from vancomycin to linezolid/daptomycin as empiric therapy of MRSA infections
- Antimicrobial prophylaxis during chest tube placement in ling transplant patients
- PK/PD evaluation of loading doses for extended/continuous infusion beta-lactams